Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

34.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
34.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

248
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
248
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

1.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

576
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
576
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

787
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
787
Allergic Reactions02:06

Allergic Reactions

29.3K
Overview
29.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review.

Journal of medical economics·2026
Same author

Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2026
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

[Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)·2025
Same author

Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidence.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Unmet needs in hereditary angioedema: an international survey of physicians.

Orphanet journal of rare diseases·2025

Related Experiment Video

Updated: Oct 18, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.3K

Hereditary Angioedema in Pregnancy.

Irene I Chair1, Karen E Binkley2, Stephen D Betschel3

  • 1Postgraduate Trainee, Clinical Immunology and Allergy, Department of Internal Medicine, University of Toronto.

Obstetrical & Gynecological Survey
|September 29, 2021
PubMed
Summary

Hereditary angioedema (HAE) management during pregnancy requires careful consideration. Plasma-derived C1 inhibitor concentrate is a safe and effective treatment for HAE attacks and prevention in pregnant patients.

More Related Videos

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

989
In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

411

Related Experiment Videos

Last Updated: Oct 18, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.3K
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

989
In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

411

Area of Science:

  • Immunology
  • Genetics
  • Obstetrics

Background:

  • Hereditary angioedema (HAE) is a rare genetic disorder causing unpredictable, potentially life-threatening swelling attacks.
  • Pregnancy significantly impacts HAE course and treatment options, necessitating specialized care for women of childbearing age.
  • Accurate diagnosis and understanding of HAE mechanisms are crucial for effective patient management.

Purpose of the Study:

  • To provide a comprehensive overview of hereditary angioedema.
  • To establish guidelines for managing pregnant patients with HAE.
  • To inform clinicians on recognizing and treating HAE in pregnancy.

Main Methods:

  • Literature search of English-language articles on PubMed and Ovid MEDLINE.
  • Keywords used: "hereditary angioedema" and "pregnancy".
  • Additional relevant articles identified from reference lists.

Main Results:

  • Data synthesized from observational studies, case reports, and reviews indicate variable HAE presentation during pregnancy.
  • Plasma-derived C1 inhibitor concentrate demonstrated safety and efficacy for acute attack treatment and prophylaxis in pregnant patients.
  • Successful pregnancy and delivery are achievable with appropriate medical recognition, understanding, and management.

Conclusions:

  • Clinicians should suspect HAE in cases of recurrent angioedema without urticaria or unexplained severe abdominal pain.
  • Individualized treatment plans are essential for pregnant patients with HAE.
  • Collaborative care involving experienced clinicians is vital for optimal outcomes.